**Supplemental Table: Characteristics of participants receiving 12 weekly-doses of isoniazid/rifapentine**

|  |  |
| --- | --- |
| **Participant Characteristics (n=463)** | **n (%)** |
|
| **Gender**  |  |
| Male | 326 (70.4) |
| Female | 137 (29.6) |
|  |  |
| **Median age (years)** | 36 years (range: 20–71 years) |
|  |  |
| **Age Categories (years)**  |  |
| (20-29) | 102 (22.0) |
| (30-39) | 193 (41.7) |
| (40-49) | 112 (24.2) |
| (50+) |  56 (12.1) |
|  |  |
| **Race/Ethnicity** |  |
| American Indian/Alaskan Native  | 7 (1.5) |
| Asian  | 9 (1.9) |
| Black/African American, non-Hispanic  | 35 (7.6) |
| White, non-Hispanic  |  55 (11.9) |
| Hispanic | 357 (77.1) |
|  |  |
| **Risk Factors**  |  |
| Foreign-born | 310 (67.0)  |
| Contact to a TB case |  92 (19.9) |
|  |  |
| **Medical Conditions**  |  |
| Diabetes | 32 (6.9) |
| Mental health disordera |  78 (16.9) |
| Renal disease |  7 (1.5) |
| Hepatitis B | 2 (0.4) |
| Hepatitis C | 34 (7.3) |
| HIV | 2 (0.4) |
|  |  |

a Not related to substance abuse